In Silico Analyses of Epicoccamides on Selected Leishmania Trypanothione Reductase Enzyme-based Target

Abstract

Fatima, et al.: In silico analyses of epicoccamides on Leishmania trypanothione-reductase Leishmaniasis is a protozoal infection, which presents a broad spectrum drug resistance and causes diseases ranging from asymptomatic infections to significant mortality. The enzyme, trypanothione reductase from Leishmania infantumis is essential for the parasite survival. It is an attractive target to design new less toxic drugs against leishmaniasis as found absent in mammalian cells. The antileishmanial activity of epicoccamide derivatives was studied by in silico approaches. The crystallographic structure of trypanothione reductase was obtained from the protein data bank (ID: 2W0H) database. Binding mode of the epicoccamide inhibitors showed that they are stabilized in the active site of enzyme through hydrogen bond and hydrophobic interactions. These derivatives (A-D) showed significant binding affinities with trypanothione reductase with binding energies: -13.21, -13.44, -13.31, and -13.52 kcal/mol, respectively.The present study revealed new and effective antileishmanial compounds that can gain pharmaceutical importance.

Fungal Endophytes: Microfactories of Novel Bioactive Compounds with Therapeutic Interventions; A Comprehensive Review on the Biotechnological Developments in the Field of Fungal Endophytic Biology over the Last Decade

“…These derivatives interacted with the active site of the enzyme through hydrogen bonds and hydrophobic interactions, leading to their stabilization. Epicoccamide derivatives exhibited high bonding energies with the trypanothione reductase of −13.31, −13.44, −13.31, and −13.32 kcal/mol, respectively [267,268] (Table 8, Figure 11).…”